- Genprex’s
collaborators at MD Anderson reported positive preclinical data for the
combination of the TUSC2 gene with an anti-PD1 antibody for the treatment
of non-small cell lung cancer
- The
TUSC2 gene, a tumor suppressor gene, is the active agent in Genprex’s
Oncoprex immunogene therapy, the company’s lead drug candidate for the
treatment of lung cancer
- In
combination with pembrolizumab, the TUSC2 gene significantly slowed tumor
growth in mice with human immune cells
- Lung
cancer ranks among the malignancies that are expected to increase the most
in the coming years, especially among women; immunotherapy solutions may
provide an effective option for the treatment of such cancers
Genprex Inc. (NASDAQ: GNPX), a clinical stage gene therapy
company, reported in a press release that its University of Texas MD Anderson
Cancer Center collaborators have recorded positive preclinical data in a lung
cancer treatment study (http://ibn.fm/Uws4i).
The results of the study, which analyzed the combination of the TUSC2 gene and
anti-PD1 antibody pembrolizumab, were presented in a poster at the 2019
American Association of Cancer Research Meeting. TUCS2 is a tumor suppressor
gene and the active agent in Genprex’s Oncoprex immunogene therapy.
The poster data showed that TUCS2 in combination with
checkpoint blockade was more effective than checkpoint blockade alone in
increasing the survival of mice with human immune cells (humanized mice) that
had metastatic lung cancer. TUCS2 in combination with pembrolizumab
demonstrated the ability to significantly slow tumor growth.
Genprex is working to bring its lead drug candidate, Oncoprex,
to market. According to Genprex CEO and Chairman Rodney Varner, Oncoprex offers
a systemic, targeted approach to the treatment of non-small cell lung cancer.
Oncoprex is administered intravenously and absorbed by the tumor cells. It then
expresses proteins that are either missing or found in low quantities. Through
this mechanism, Oncoprex interrupts the signaling pathways that cause the
replication and proliferation of cancer cells.
In addition, Oncoprex modulates the immune response against
cancer and re-establishes the pathways for programmed cancer cell death.
Genprex and its collaborators have shown that the company’s
patented, targeted nanoparticle delivery system provides up to 25-times greater
uptake of the TUCS2 gene in tumor cells than in normal cells. Oncoprex has also
shown a favorable safety profile in comparison to other lung cancer treatment
options.
According to the Centers for Disease Control and Prevention
(CDC), the number of new cancer cases in the U.S. in men is expected to
increase by 24 percent by 2020. The increase in women is expected to be 21
percent. The kinds of cancer expected to increase the most include melanoma,
prostate and lung cancer (http://ibn.fm/9J744).
New lung cancer cases have been maintaining a steady level
among men, but are increasing more rapidly in women. In the period from 2015 to
2030, standardized lung cancer mortality rates among women are expected to
increase from 11.2 to 16.0, marking an increase of over 40 percent (http://ibn.fm/w7Ypx).
Due to such developments and scientific advances, the global
cancer immunotherapy market is anticipated to reach $152.83 billion by 2024,
according to a Research and Markets report (http://ibn.fm/QifFM).
Genprex continues to focus on the development of new
treatments for cancer as a part of its mission to develop innovative gene
therapy options and improve patient outcomes. The company already has more than
30 issued patents for its platform technologies and gene therapies.
Oncoprex, the company’s lead drug candidate, is an
investigational immunogene therapy for non-small cell lung cancer that works by
administering cancer fighting genes encapsulated in nanoscale hollow spheres
(nanovesicles).
For more information, visit the company’s website at www.Genprex.com
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About QualityStocks
QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential. We offer several ways for investors to learn more
about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment